SIC
EW icon

Samalin Investment Counsel’s Edwards Lifesciences EW Stock Holding History

Samalin Investment Counsel’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-39
Closed -$3K – 251
2019
Q4 		$3K Buy
+39
New +$3.04K ﹤0.01% 491

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Samalin Investment Counsel's EW Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Edwards Lifesciences (EW) in Q1 2020, closing a stake of 39 shares — an estimated $3K sold.

Samalin Investment Counsel first reported a position in EW in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 1,019 funds tracked by Wall St. Rank hold EW as of Q1 2020.

  • Samalin Investment Counsel reported no remaining Edwards Lifesciences position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 39 Edwards Lifesciences shares in Q1 2020, an estimated $3K.
  • Samalin Investment Counsel first reported a position in Edwards Lifesciences in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's Edwards Lifesciences position peaked at $3K in Q4 2019.
  • 1,019 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.